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888-6 The HEP@NET Study: An Internat-Baaed Registry 
Examining the Eff icacy of Heperin Coating in Patients 
Undergoing Coronary Stent Implantation 
Roxana Mehran. C. Lotan, I. Krenjec, E. Holmer, K. Haase, E. Camenzind, M. Zelizko, L. 
Malllard, R. Beabra-Gomes, M. G. Vandormael, A. J. Lansky, G. Dangas, G. W. Stone, 
Dale T. Ashby, M B. Leon, Cardiovascular Research Foundation, New York, New York. 
Background: Despite optimal anti-piatalet herapy, subacute stent thrombosis (SST) 
occurs in -1% of pts, and more frequently in higher dsk subgroups. Whether antithrom- 
botic stent coatings, such as heparin, may further reduce SST is unknown. We designed 
a global multicenter egistry to examine the "real-wodd' rates of SST in pts receiving non 
coated and heparin coated (Hepacoat TM) Bx Velocity stants. All patients received an 
anti-platalet regimen of plavix for 2-4 weeks and aspirin indefinitely. 
Methods: The Hap@net study plans to enroll 4,000 pts (134 sites in 23 countries) in 
which consecutive blocks of pts undergoing stent implantation at each site are treated 
with either the hepadn coated (Hepacoat TM) or non coated BX Velocity stent. The pri- 
mary endpoint is SST at 30-days. Enrollment is in progress; thus far 1,962 pts have 
reached 30 day follow-up. 
Results: There were no significant differences in baseline demographic and angio- 
graphic features in the 2 groups. Procedural data and 30-day clinical results are in the 
Table. 
Hepecoat Stent Non Coated Stent P Value 
(N=897) (N=1065) 
De novo lesion (%) 95.6 96.1 
Reference vessel diameter (mm) 3.12 + 3.2 3.19 + 2.2 
Diameter stanosis pre (%) 89.1 + 10.7 87.3 + 11.8 
Diameter stenosis post (%) 1.9 + 9.0 2.0 + 7.0 
Procedural GP lib/Ilia use (%) 23.3 21.4 
30 day: 0.6 1.1 
Stent thrombosis (%) 
Cardiac death (%) 0.3 0,1 
MI (%) 0.5 0.6 
TLR (%) 0.2 0.7 
MACE (%) 0.8 1.2 
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11:45 a.m. (0.7-3.7)% CD 34+ hemopoietic stem calls, 20.2 (10.6-31.6)% CD15+ and 27.3 (16.7- 
30.3)% CD11b+ granulocytic precursor cells, and 6.0 (2.3-12.1)% CD3+ T cells. All the 
microbiological cultures were negative. After a mean follow-up of 5-~ 2 months, there was 
an improvement in the angina score (2.0-J: 0.7 vs. 2.6+ 0.5, p=0.07) and reduction of daily 
TNG consumption (0.9¢ 1.2 vs. 2.8+ 0.4, p=O.02). 
Conclusions. Our preliminary results suggest that EM guided percutaneously delivery of 
autologous BMCs is a safe and feasible method for therapeutic angiogenesis. The long- 
term safety and therapeutic implications of using autologous BMCs as a call-based 
angiogenic therapy require future studies. 
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889FO-3 Percutaneous Tranavenous Cellular Cardiomyoplaaty: 
A Novel Nonsurgical Approach for  Myocardial Cell 
Transplantation 
~raiq A. Thomoson. Boris A. Nasseri, Joshua Makower, Irina Pomerantseva, Theodore 
Lamson, John Y. Chang, Michael McGarry, Mark C. Fishman, Joseph P. Vacanti, 
Stephen N. Oestede, Massachusetts General Hospital, Boston, Massachusetts, 
TrsnsVascular, Inc., Menlo Park, California. 
Background: To better understand the biological and technical attributes of stem and 
progenitor call therapy for the failing head, we are developing a large animal model and 
evaluating non-surgical means of intramyocardial call introduction. 
Method8: We harvested bone marrow from Yorkshire swine (n=6; 50-60kg), selected 
and expanded stromal calls in culture, tagged them with the gane for green fluorescent 
protein, and resuspendsd them in collagen hydrogal. Working through the coronary 
0.62 sinus, a specialized catheter system was easily delivered to the antedor intsrventricular 
0.57 coronary vein. The composite catheter system (TransAccass TM) incorporates a phased- 
array ultrasound tip for guidance and a sheathed, extendable nitinol needle for transvas- 
0.03 cular myocardial access. We advanced a microinfusion catheter through the needle, 
0.85 deep into remote myocardium and injected the autologous call-hydrogel suspension. Ani- 
mals were sacrificed at days 0(N=2), 14(N=1 ,+1 control/collagen biogel only), and 28 
0.32 (N=2), and the hearts were excised and examined. 
0.36 Reeulte: We gained widespread intramyocardial access to the anterior, lateral, saptal, 
apical, and inferior walls from the anterior interventicular coronary vein. No death, car- 
0.58 diac tamponads, ventdcular arrhythmia or other procedural complications occurred. 
Gross inspection demonstrated no evidence of myocardial perforation, and biogel/black 
0.99 tissue dye was well localized to sites corresponding to fluoroscopic landmarks for deliv- 
0.t 5 ery. Microscopic analysis demonstrated needle and microcathetar t acts, biogal delivery, 
0.40 and preliminary evaluation suggested the presence of fluorescentiy labeled cells. This 
autologous, bone marrow cell population is currently being assessed by immunohis- 
tochemical analysis. 
Conclusion: Percutaneous intramyocardial access is safe and feasible by a trans- 
venous approach through the coronary venous system. The swine offers an opportunity 
to refine the cells and approaches used for cellular cardiomyoplasty. 
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889FO-4 Azacytidlne Stimulated Bone Marrow Derived Human 
Mesenchymal Stem Cells: Percutaneoua 
Intramyocardial De,very 
Kai Jaouet, Korff Krausa, Norbert Stuta, Axal Zander, Kad-Heinz Kuck, SL Georg 
Hospital, Dept. of Cardiology, Hamburg, Germany, University of Hamburg, Hamburg, 
Germany, 
Background: Transplantation of myocytes into scarred myocardium has been shown to 
improve heart function and may therefore be a promising new strategy for the treatment 
of patients with ischemic heart disease. We have isolated human mssenchymal stem 
cells (hMSC) from bone marrow that can be induced to express a myogenic phenotype. 
In addition we determined the feasibility of percutaneous delivery of these cells into pig 
myocardium. 
Methods: Human MSCs were isolated and cultivated according to Caplan's method. 
After the second passage the adherent hMSCs were treated by a 24h stimulus of 5-aza- 
cytidine (101~mol/ml). 10-14 days later immunohistochemical nalysis was done using 
smooth muscle actin (SMA), troponin T-C, alpha-actinin, alpha-SR-1, CD31, AC133, and 
fibroblast specific sntbodies. Cells were delivered into pig myocardium (single injection = 
2 - 6 million cells) using the NOGATM system equipped with the MyoStar injection cathe- 
ter (Biosense Webster Inc.), which possesses both injection and 3-dimensional naviga- 
tion capabilities. In addition myogenic precursors were injected into culture flasks for 
determination of viability, morphology and mitotic activity. 
Results: Azacytidins gives rise to more than 80% of cells expressing a myogenic pheno- 
type compared to non-induced controls. Treated cells are positive for muscle specific 
antigens (SMA) and do not express mesenchymal stem call and fibroblast specific anti- 
gens. Changes in viability, morphology and mitotic activity could not be observed after 
passage through the catheter. Injection sites could precisely be identified macroscopi- 
cally. No pericardial effusion occurred. 
Conclusion: 1.5-azacytidine treatment of hMSCs results in over 80% SMA positive cells 
indicating a myogenic differentiation induction. 2. Passaging the cells through the Bio- 
sense injection catheter (175 cm) is feasible and no disadvantageous effects on viability, 
morphology and mitotic activity could be observed. 3. Therefore the injection catheter is a 
valuable tool for further investigations on percutaneous intramyocardial cell transplanta- 
tion strategies. 
Conclusions: In this ongoing global intemet-basad registry of "real world' pts, the Hepa- 
coat TM stant is (i) associated with similar procedural results as the bare Bx-Velocity stent; 
(ii) at 30 day follow-up, pts treated with Hepacoat TM slants have very low SST (0.6%) - 
45% lower than with non-coated stents. These encouraging preliminary results may 
establish the Hepacoat TM stents as a recommended therapy for lesion/patient subsets at 
high dsk for SST. 
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889FO-2 Therapeutic Angiogenesis  of Ischemic Myocardium 
Using Percutaneous Delivery of Autologous Bone 
Marrow Cells 
Huno-Fat Tse. Chu-Pak Lau, Yok-Lam Kwong, Department of Medicine, University of 
Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong. 
Background. Recent studies suggested that intramyocardial injection of bone marrow 
calls (BMCs) induces neovasculadzation i  ischemic myocardium. 
Methods. We evaluated the safety and feasibility of electromechanical mapping (EM) 
(NOGA, Biosense) guided injection of autologous BMCs for neovasculadzation in 5 
males (mean age: 60-J:10 yrs) with medically refractory angina (mean anti-angina medi- 
cations: 4±1, mean ejection fraction:48± 10%) and failed previous conventional revascu- 
larization procedures. All patients (pts) had documented reversible pedusion defects on 
SPECT scan. 40 ml of marrow blood was aspirated from the dght lilac crest and mononu- 
clear cells were isolated by Ficoll density gradient centdfugation. The BMCs was then re- 
suspended in phosphate buffered saline enriched with 10% autologous plasma at a con- 
centration of 107/ml. All pts underwent EM to identify target ischemic area (unipolar volt- 
age >10 mV, linear local shortening <12%) and to avoid scar area (unipolar voltage<5 
mV). A 27G injection needle catheter was manipulated to the ischemic region and 
intramyocardial injections of 0.1 ml of BMCs (108 cells / injection) were evenly delivered 
as guided EM. 
Results. Successful BMCs injection to 8 ischemic regions in 5 pts was performed (mean 
no. of injection: 18i-6/pt). The mean procedural time was 105+ 38 mins. No pedcardial 
effusion, elevation of cardiac enzyme or ventricular arrhythmias was observed after pro- 
cedure. As determined by flow cytomstry, BMCs suspension contained a median of 1.7 
